Navy General Hospital, Beijing is the lead sponsor of 15 current clinical trials in our China register. 10 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are R-Idaram, Azacitidine and Azacytidine. The most-studied condition is Venous Thromboembolism.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas
NCT06176027 · ClinicalTrials.gov ↗ · Relapsed Peripheral T-Cell Lymphomas, Refractory Peripheral T-Cell Lymphomas
Drug: Azacytidine |
Phase 1/2 | Recruiting | 2024-10 | China |
|
Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL
NCT02836158 · ClinicalTrials.gov ↗ · Primary Central Nervous System Lymphoma
Drug: R-Idaram |
Phase 2/3 | Recruiting | 2010-09 | China |
|
Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy
NCT02657785 · ClinicalTrials.gov ↗ · Primary Central Nervous System Lymphoma
Drug: R-Idaram |
Phase 2/3 | Recruiting | 2010-09 | China |
|
Pola-ZR2P in Previously Untreated DLBCL
NCT06664411 · ClinicalTrials.gov ↗ · Diffuse Large B-cell Lymphoma
|
Phase 2 | Recruiting | 2024-09 | China |
|
Smart Technology Facilitated Patient-centered Care for Patients With Pulmonary Thromboembolism
NCT06382038 · ClinicalTrials.gov ↗ · Venous Thromboembolism, Pulmonary Thromboembolisms, Digital Health
|
Not applicable | Recruiting | 2026-08 | China |
|
CtDNA After Chemotherapy in Elderly Patients With Acute Leukemia
NCT04157569 · ClinicalTrials.gov ↗ · Acute Leukemia
|
Observational | Recruiting | 2019-11 | China |
|
Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD
NCT02918188 · ClinicalTrials.gov ↗ · Chronic Graft-versus-host Disease
|
Phase 2 | Recruiting | 2016-01 | China |
|
Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
NCT06190067 · ClinicalTrials.gov ↗ · Relapsed Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Drug: Azacitidine |
Phase 2 | Recruiting | 2023-10 | China |
|
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
NCT06503263 · ClinicalTrials.gov ↗ · Diffuse Large B-cell Lymphoma
Drug: Zanubrutinib |
Phase 2 | Recruiting | 2024-08 | China |
|
VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS
NCT06471946 · ClinicalTrials.gov ↗ · Higher-risk Myelodysplastic Syndromes
Drug: Venetoclax |
Phase 1/2 | Recruiting | 2024-10 | China |
|
CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML
NCT06470841 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia
|
Phase 2 | Not yet open | 2024-09 | China |
|
Smart Technology Facilitated Patient-centered Venous Thromboembolism Management
NCT06350344 · ClinicalTrials.gov ↗ · Venous Thromboembolism, Digital Health, Health Education
|
Not applicable | Not yet open | 2024-11 | China |
|
Burden-Evaluated Active Therapy for AF Using Continuous Wearables BEAT-AF Trial
NCT07512037 · ClinicalTrials.gov ↗ · Atrial Fibrillation (AF), Digital Health Intervention, Wearable Monitoring
|
Not applicable | Not yet open | 2026-04 | China |
|
Effect of Aerobic Interval Training on Atrial Fibrillation Burden
NCT06491329 · ClinicalTrials.gov ↗ · Atrial Fibrillation, Cardiac Rehabilitation
|
Not applicable | Not yet open | 2024-08 | China |
|
Smart Technology Facilitated Patient-centered Venous Thromboembolism Management
NCT06350331 · ClinicalTrials.gov ↗ · Venous Thromboembolism, Digital Health, Health Education
|
Not applicable | By invitation | 2024-08 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 15 | 10 |
A trial with sites in more than one country appears in each of those registers.
| Sponsor | Trials |
|---|---|
| University of Dublin, Trinity College | 1 |
| Inari Medical | 1 |
Sponsors with the most current trials registered for this condition.
Navy General Hospital, Beijing is the lead sponsor of 15 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 10 of its 15 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 5 drugs and biologicals as interventions. The most frequent are R-Idaram (2), Azacitidine (1), Azacytidine (1), Venetoclax (1) and Zanubrutinib (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.